BTIG initiated coverage of Venus Concept (NASDAQ:VERO) with a “buy” rating and $7 price target. The stock closed at $3.52 on June 2. “It is not an easy time to be an aesthetics device company amidst the COVID-19...
SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...
CohBar (NASDAQ:CWBR) was added to the small-cap Russell 2000 index during its latest reconstitution. The company also sold common stock through its existing at-the-market (ATM) offering, with net proceeds of about $4.4...
SVB Leerink initiated coverage of Applied Molecular Transport (NASDAQ:AMTI) with an “outperform” rating and $32 price target. The stock closed at $25.80 on June 29. “We believe Applied’s emerging translocation...
Alliance Global Partners launched coverage of iBio (NYSE American:IBIO) with a “buy” rating and price target of $2.55. The stock closed at $1.61 on June 25 but has traded as high as $2.69 on June 26. Shares of iBio will...
H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...
BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...
Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team. With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...
H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...
Ladenburg Thalmann launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $60 price target. The stock closed at $14.31 on June 19. Forte is focused on the treatment of inflammatory skin diseases...